TOKYO -- China's indictment of a Japanese employee at Astellas Pharma has heightened safety concerns among the Japanese business community there, with companies seeking greater clarity and transparency regarding Beijing's counterespionage efforts.
The man, who is an executive at the Japanese drugmaker's China unit, was detained on suspicion of spying in 2023. He has been posted in China for over 20 years combined, and previously served as vice chair of the Japanese Chamber of Commerce and Industry in China.
